The biotechnology company Orikine Bio, a member of Catalonia.health, has received €2.7 million in investment from SICC Innvierte of CDTI Innovación together with fund managers Asabys Partners (Sabadell Asabys Health Innovation Investments II, FCR and Sabadell Asabys Health Innovation Investments 2B, SCR SA) and AdBio Partners (AFB Seed Fund II), also members of Catalonia.health.
Funding for Innovative Therapies
With this capital injection, the company will continue driving the development of a new generation of therapies for autoimmune, inflammatory and oncological diseases.
CDTI Innovación, through Innvierte, has closed this investment operation for a total amount of €2.7 million. Thanks to this participation, CDTI Innovación contributes to improving people's health and wellbeing, promoting the development of products that accelerate patient recovery.
Immune Reprogramming Technology
Orikine Bio has a team composed of experts in biotechnology, immunology, protein engineering and business development. Its main objective is to develop therapies capable of "reprogramming" the immune system, similar to how software engineers rewrite faulty code to repair computer systems.
Its proprietary platform Foldikine™ designs bispecific cytokines, molecules that send precise and targeted instructions to immune cells in a specific, effective and safe manner. By reprogramming these cells, they restore proper immune function and offer innovative solutions for conditions such as autoimmune diseases and chronic inflammation.
Boost to Growth and Development
With this new investment and the technological momentum represented by the Foldikine™ platform, Orikine Bio strengthens its growth potential and consolidates its commitment to developing innovative therapies that improve people's quality of life.
The operation represents a step forward in translating scientific knowledge into high-impact solutions for the healthcare system, positioning the company as a reference in the development of therapies targeting the immune system.
Comments